MedTrace Logo

Effect of Adalimumab Therapy on Psoriasis Patient

NCT05889338 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2023-06-05

No results posted yet for this study

Summary

to evaluate the impact of adalimumab therapy on quality of life in patient with severe psoriasis.

Conditions

  • Psoriasi

Interventions

DRUG

adalimumab and methotrexate

Adult patients (\> 18 years) with severe psoriasis who will start treatment with either adalimumab or methotrexate

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-30
Primary Completion
2024-01-31
Completion
2024-01-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05889338 on ClinicalTrials.gov